Cholecystokinin peptides, dopamine and schizophrenia--a review
- PMID: 2868491
- DOI: 10.1016/0278-5846(85)90011-9
Cholecystokinin peptides, dopamine and schizophrenia--a review
Abstract
CCK-IR is co-localized with DA in some DA neurons projecting to limbic structures. The extent of the co-localization is species dependent. The co-localization of CCK and DA is of interest in view of the DA hypothesis of schizophrenia and the putative role of limbic dysfunction in the pathophysiology of this disorder. In animals biochemical, electrophysiological and behavioural studies point to an interaction between CCK and DA. Whereas some investigations point to an inhibitory effect on DA function, which would be compatible with a potential antischizophrenic action, others point to an enhancement or no effect. CCK peptides show a neuroleptic-like profile in several screening tests for neuroleptics but not in all studies. In man there is endocrinological evidence for an inhibitory effect of CCK-33 and CCK-8 on DA function. However, alternate explanations are possible. CSF CCK-IR is unchanged or decreased in schizophrenia. Autopsy investigations have shown significant decreases, increases or no change in brain CCK-IR concentrations and a decrease in CCK-33 binding in schizophrenia. Eight of 11 clinical trials with CER, CCK-8 or CCK-33 have shown a therapeutic effect in schizophrenia; only two of these eight trials have been double-blind studies. The three controlled investigations which have shown no effect have used only small patient populations. None of the trials have used an active placebo. It is difficult to reconcile the apparent long duration of antipsychotic activity with the short half-life of the peptides and problems of the peptides in crossing the blood brain barrier. Despite these apparent anomalies information to date is sufficiently impressive to warrant further detailed investigation of CCK-DA-interactions and the evaluation of the clinical effects of a variety of CCK peptides and related compounds, natural and synthetic, which may more easily cross the blood brain barrier and which may show regional selectivity in site of action in brain.
Similar articles
-
Cholecystokinin-dopamine coexistence: electrophysiological actions corresponding to cholecystokinin receptor subtype.J Neurosci. 1986 Oct;6(10):3039-43. doi: 10.1523/JNEUROSCI.06-10-03039.1986. J Neurosci. 1986. PMID: 3760947 Free PMC article.
-
The effects of cholecystokinin-like peptides in schizophrenics and normal human subjects.Ann N Y Acad Sci. 1985;448:542-52. doi: 10.1111/j.1749-6632.1985.tb29947.x. Ann N Y Acad Sci. 1985. PMID: 3896099 Clinical Trial.
-
In vivo sulfation of cholecystokinin octapeptide. Possible interactions of the two forms of cholecystokinin with dopamine in the brain.Ann N Y Acad Sci. 1985;448:293-305. doi: 10.1111/j.1749-6632.1985.tb29925.x. Ann N Y Acad Sci. 1985. PMID: 2862826
-
Two faces of cholecystokinin: anxiety and schizophrenia.Fundam Clin Pharmacol. 1996;10(2):116-26. doi: 10.1111/j.1472-8206.1996.tb00154.x. Fundam Clin Pharmacol. 1996. PMID: 8737954 Review.
-
Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.Life Sci. 2003 Jun 27;73(6):727-39. doi: 10.1016/s0024-3205(03)00393-x. Life Sci. 2003. PMID: 12801594 Review.
Cited by
-
Cholecystokinin binding sites in the rat forebrain: effects of acute and chronic methamphetamine administration.J Neural Transm. 1989;77(2-3):181-95. doi: 10.1007/BF01248931. J Neural Transm. 1989. PMID: 2760604
-
Generalised anxiety disorder: treatment options.Drugs. 2002;62(11):1635-48. doi: 10.2165/00003495-200262110-00005. Drugs. 2002. PMID: 12109925 Review.
-
Characterization of [3H]cholecystokinin octapeptide binding to mouse brain synaptosomes: effects of neuroleptics.Neurochem Res. 1987 Aug;12(8):729-37. doi: 10.1007/BF00970529. Neurochem Res. 1987. PMID: 3627361
-
Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.Curr Neuropharmacol. 2021;19(7):925-938. doi: 10.2174/1570159X18666201113145143. Curr Neuropharmacol. 2021. PMID: 33185164 Free PMC article. Review.
-
CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.Psychopharmacology (Berl). 1989;99(3):409-15. doi: 10.1007/BF00445568. Psychopharmacology (Berl). 1989. PMID: 2574480
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical